Once-daily diabetes drug approved FDA approved 10 mg dapagliflozin and 5 mg saxagliptin (Qtern, AstraZeneca), to treat type 2 diabetes. Six diseases reap benefits of biomarkers, genetic tests March 02, 2017 By Karen Appold Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening. How obesity and related conditions are skyrocketing February 16, 2017 By Rachael Zimlich RN Obesity is rising in children and teens, according to a new report, but other health problems tied to obesity are increasing, too. Get smart about metabolic syndrome! February 01, 2017 By Chrystal Wittcopp MD As pediatricians we are all too aware of our nation’s struggle with childhood overweight and obesity. Approximately 1 of every 5 children that we see in the office every day is obese. Despite tremendous efforts to reverse this trend, it is clear we are in this battle for the long haul. How to test kids for diabetes February 01, 2017 By Lisette Hilton Testing glycated hemoglobin (HbA1c) appears to predict children’s diabetes risk as well as fasting plasma glucose and 2-hour postload plasma glucose, according to a study on more than 2000 American Indian children. New device could be breakthrough for diabetics January 02, 2017 By Christine Blank FDA recently expanded approval of the G5 Mobile Continuous Glucose Monitoring System (Dexcom) to allow for replacement of fingerstick blood glucose (sugar) testing for diabetics. New diabetes combo drug available soon December 19, 2016 By Christine Blank A new combination drug for type 2 diabetes will available in the US in the coming months. New drug indication could net more than $1 billion December 05, 2016 By Christine Blank FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion. FDA approves 2 injectable diabetes drugs November 28, 2016 By Christine Blank Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.